PT3004106T - Inibidores de pi3 delta e gama quinase seletivos duplos - Google Patents

Inibidores de pi3 delta e gama quinase seletivos duplos

Info

Publication number
PT3004106T
PT3004106T PT147320196T PT14732019T PT3004106T PT 3004106 T PT3004106 T PT 3004106T PT 147320196 T PT147320196 T PT 147320196T PT 14732019 T PT14732019 T PT 14732019T PT 3004106 T PT3004106 T PT 3004106T
Authority
PT
Portugal
Prior art keywords
delta
kinase inhibitors
dual selective
gamma kinase
gamma
Prior art date
Application number
PT147320196T
Other languages
English (en)
Inventor
K V S Vakkalanka Swaroop
K Bhavar Prashant
Viswanadha Srikant
Babu Govindarajulu
Original Assignee
Rhizen Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A
Publication of PT3004106T publication Critical patent/PT3004106T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT147320196T 2013-06-07 2014-06-04 Inibidores de pi3 delta e gama quinase seletivos duplos PT3004106T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2501CH2013 2013-06-07
IN5567CH2013 2013-12-03

Publications (1)

Publication Number Publication Date
PT3004106T true PT3004106T (pt) 2017-11-27

Family

ID=50980341

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147320196T PT3004106T (pt) 2013-06-07 2014-06-04 Inibidores de pi3 delta e gama quinase seletivos duplos

Country Status (31)

Country Link
US (3) US9790224B2 (pt)
EP (1) EP3004106B1 (pt)
JP (1) JP6499165B2 (pt)
KR (1) KR102292853B1 (pt)
CN (1) CN105358560B (pt)
AP (1) AP2015008888A0 (pt)
AR (1) AR096543A1 (pt)
AU (1) AU2014276476B2 (pt)
BR (1) BR112015030385B1 (pt)
CA (1) CA2913226C (pt)
CL (1) CL2015003562A1 (pt)
CY (1) CY1119615T1 (pt)
DK (1) DK3004106T3 (pt)
EA (1) EA029017B1 (pt)
ES (1) ES2648094T3 (pt)
HK (1) HK1217949A1 (pt)
HR (1) HRP20171795T1 (pt)
HU (1) HUE035237T2 (pt)
IL (1) IL242761B (pt)
LT (1) LT3004106T (pt)
MX (1) MX366449B (pt)
NO (1) NO3004106T3 (pt)
PH (1) PH12015502698A1 (pt)
PL (1) PL3004106T3 (pt)
PT (1) PT3004106T (pt)
RS (1) RS56606B1 (pt)
SG (1) SG11201509992RA (pt)
SI (1) SI3004106T1 (pt)
TW (1) TWI615144B (pt)
WO (1) WO2014195888A1 (pt)
ZA (1) ZA201508708B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
PT2968552T (pt) 2013-03-14 2020-05-18 Scripps Research Inst Anticorpo dos agentes alvo, combinações e uso para os mesmos
SG11201510011VA (en) 2013-06-07 2016-01-28 California Inst Biomedical Res Small molecule inhibitors of fibrosis
BR112015030385B1 (pt) * 2013-06-07 2020-08-18 Rhizen Pharmaceuticals S.A. Composto, composto para uso e composição farmacêutica
US10336735B2 (en) 2014-12-10 2019-07-02 The Scripps Research Institute Small molecule inhibitors of fibrosis
AU2015369665A1 (en) * 2014-12-23 2017-06-29 Pharmacyclics Llc BTK inhibitor combinations and dosing regimen
US20200289520A1 (en) * 2017-12-06 2020-09-17 Rhizen Pharmaceuticals Sa Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
US20230167116A1 (en) 2020-05-14 2023-06-01 Rhizen Pharmaceuticals Ag Purine derivatives as sik-3 inhibitors
WO2023125418A1 (zh) * 2021-12-31 2023-07-06 同润生物医药(上海)有限公司 一种苯磺酸盐结晶及其制备方法
WO2023125419A1 (zh) * 2021-12-31 2023-07-06 同润生物医药(上海)有限公司 一种己二酸盐结晶及其制备方法
WO2023123742A1 (zh) * 2021-12-31 2023-07-06 同润生物医药(上海)有限公司 PI3Kδ/γ双重抑制剂化合物的半富马酸盐结晶及其制备方法
WO2023130334A1 (zh) * 2022-01-07 2023-07-13 同润生物医药(上海)有限公司 一种色烯-4-酮化合物及其中间体的制备方法
WO2023209634A1 (en) 2022-04-29 2023-11-02 Rhizen Pharmaceuticals Ag A dual selective pi3k delta and gamma inhibitors and/or a salt-inducible kinase 3 inhibitor for treating solid tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2496567T3 (pl) * 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Nowe benzopiranowe modulatory kinazy
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
SG194718A1 (en) * 2011-05-04 2013-12-30 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
EA032812B1 (ru) 2012-05-04 2019-07-31 Ризен Фармасьютикалз Са Способ получения оптически чистых и необязательно замещенных производных 2-(1-гидроксиалкил)хромен-4-она и их применение при получении лекарственных препаратов
BR112015030385B1 (pt) * 2013-06-07 2020-08-18 Rhizen Pharmaceuticals S.A. Composto, composto para uso e composição farmacêutica
US20200289520A1 (en) * 2017-12-06 2020-09-17 Rhizen Pharmaceuticals Sa Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma

Also Published As

Publication number Publication date
PH12015502698B1 (en) 2016-03-14
BR112015030385B1 (pt) 2020-08-18
TWI615144B (zh) 2018-02-21
ZA201508708B (en) 2017-02-22
ES2648094T3 (es) 2017-12-28
CN105358560A (zh) 2016-02-24
BR112015030385A2 (pt) 2017-07-25
AP2015008888A0 (en) 2015-11-30
CA2913226C (en) 2023-01-03
NO3004106T3 (pt) 2018-01-27
US11466006B2 (en) 2022-10-11
TW201517908A (zh) 2015-05-16
US20210032248A1 (en) 2021-02-04
CL2015003562A1 (es) 2016-08-05
EA029017B1 (ru) 2018-01-31
IL242761B (en) 2018-11-29
MX2015016741A (es) 2016-11-14
JP6499165B2 (ja) 2019-04-10
CA2913226A1 (en) 2014-12-11
WO2014195888A1 (en) 2014-12-11
HUE035237T2 (hu) 2018-05-02
EP3004106B1 (en) 2017-08-30
EP3004106A1 (en) 2016-04-13
CY1119615T1 (el) 2018-04-04
JP2016520644A (ja) 2016-07-14
LT3004106T (lt) 2018-02-26
NZ714465A (en) 2021-03-26
HK1217949A1 (zh) 2017-01-27
US20170334914A1 (en) 2017-11-23
US20140364447A1 (en) 2014-12-11
AR096543A1 (es) 2016-01-13
AU2014276476A1 (en) 2015-12-10
CN105358560B (zh) 2017-03-08
MX366449B (es) 2019-07-09
HRP20171795T1 (hr) 2018-01-26
PH12015502698A1 (en) 2016-03-14
KR102292853B1 (ko) 2021-08-24
RS56606B1 (sr) 2018-02-28
AU2014276476B2 (en) 2018-05-10
SI3004106T1 (en) 2018-03-30
PL3004106T3 (pl) 2018-01-31
DK3004106T3 (en) 2017-12-04
SG11201509992RA (en) 2016-01-28
US9790224B2 (en) 2017-10-17
EA201592113A1 (ru) 2016-05-31
BR112015030385A8 (pt) 2019-12-24
US10851107B2 (en) 2020-12-01
KR20160017047A (ko) 2016-02-15

Similar Documents

Publication Publication Date Title
IL267681B (en) Selective grp94 inhibitors and their uses
HK1217949A1 (zh) 雙重選擇性 δ和γ激酶抑制劑
HK1223089A1 (zh) 激酶抑制劑及其用途
HK1217198A1 (zh) 蛋白激酶抑制劑
HK1220459A1 (zh) 激酶抑制劑
IL238564A0 (en) Combination of an antibody against 20cd with a selective pi3 kinase inhibitor
HK1219421A1 (zh) 激酶抑制劑的組合及其用途
HK1219104A1 (zh) 激酶抑制劑
HK1219057A1 (zh) 大環的鹽可誘導的激酶抑制劑
EP2986611A4 (en) CERTAIN PROTEIN KINASE INHIBITORS
EP2964225A4 (en) CAMKII INHIBITORS AND USES THEREOF
HUE050878T2 (hu) Anti-CD20 antitest és PIK3 kináz szelektív inhibitor kombinációja
GB201307155D0 (en) Kinase inhibitors
GB201304084D0 (en) Selective glycosidase inhibitors and uses thereof
GB201304083D0 (en) Selective glycosidase inhibitors and uses thereof
GB201304086D0 (en) Selective glycosidase inhibitors and uses thereof